Nov 10 2010
Emergent BioSolutions Inc. (NYSE: EBS) today announced the acceptance of four abstracts for presentation at the 52nd Annual Meeting of the American Society of Hematology (ASH) to be held from December 4 to 7 in Orlando, Florida. The presentations include an oral presentation on the results of a Phase I dose escalation, monotherapy study of TRU-016 for patients with chronic lymphocytic leukemia (CLL). TRU-016 is Emergent's humanized anti-CD37 small modular immunopharmaceutical (SMIP™) protein in development for the treatment of B-cell malignancies such as CLL and non-Hodgkin's lymphoma (NHL).
“The fact that many patients with CLL experience disease relapse tells us that there is an acute need for differentiated treatments. We are encouraged by the clinical results and look forward to the next phase in our clinical development program for TRU-016.”
"Emergent is pleased with the Phase I data and tolerability profile of TRU-016 that will be presented at ASH," said Dr. W. James Jackson, chief scientific officer at Emergent BioSolutions. "The fact that many patients with CLL experience disease relapse tells us that there is an acute need for differentiated treatments. We are encouraged by the clinical results and look forward to the next phase in our clinical development program for TRU-016."
Source:
Emergent BioSolutions Inc.
Combination treatment approach shows promise for hard-to-treat triple-negative breast cancer